Therapeutically, enhancing Cbl activity could represent a strategy to treat MyD88-driven pathologies (e.g., sepsis and autoimmune disorders), while its conditional activation mechanism minimizes the risk of immunosuppression. This evidence concerns the gene MYD88 and Sepsis.